Polymorphisms at ERCC5 and disrupted expression have been reported to increase solid tumor carcinogenesis due to the disruption of DNA excision pathways (46, 47), and in an IHC investigation study, ERCC5 encoded XPG was shown to have positive expression in breast, ovarian, and sarcoma samples (48). This evidence concerns the gene ERCC5 and sarcoma.